Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
In this episode, Urology Times® Managing Editor Ben Saylor spoke with Amy E. Krambeck, MD. She discusses the recent Journal of Endourology study, "Multi-institutional prospective randomized control trial of novel intracorporeal lithotripters: ShockPulse-SE vs Trilogy trial," for which she served as senior author. Krambeck is a professor of urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Bundled payment program covers kidney stone care
July 22nd 2024"One day, we're going to have to move away from fee for service, so we'd be wise to try to navigate those waters ahead of time, so we're not left dealing with the aftermath when someone else has implemented it for us," says Ruchika Talwar, MD.
FDA grants 510(k) clearance to Ambu’s single-use ureteroscope
July 2nd 2024"This clearance in the US of our new ureteroscopy solution not only demonstrates a market expansion for Ambu; it is a testament to the progressive shift towards single-use solutions within the field of urology," says Britt Meelby Jensen.
Data support shock wave lithotripsy for pediatric patients with kidney stones
May 28th 2024Regarding patient-reported outcomes, those who underwent URS showed higher urinary symptoms, greater pain intensity, and greater pain interference at 1 week following surgery compared with those who underwent SWL.
